Calcific uremic arteriolopathy (calciphylaxis) Review and case description

Calcific uremic arteriolopathy (CUA), previously also called calciphylaxis, is one of the several types of extra-osseous calcification and a rare and devastating disorder which most often occurs in patients with severe renal disease. CUA is a serious disorder characterized by systemic medial calcification of the arterioles that leads to ischemia and subcutaneous necrosis. The pathogenesis of CUA is poorly understood, and the optimal treatment is not known. A multi-interventional strategy (adequate dialysis, surgical debridement and wound care, hypophosphatic diet, drug treatment) is likely to be more effective than any single therapy and allows one to reduce mortality. Here we present a case of a 64-year-old female with the end-stage renal disease on chronic hemodialysis and with several secondary hyperparathyroidism (extensive two ulcers on the left leg with necrotic eschars). Our case study shows that multi-interventional strategy is likely to be more effective in treatment of CUA in patients with the end-stage renal disease on hemodialysis with several secondary hyperparathyroidism.

кальцифицирующая уремическая артериолопатия, кальцифилаксия, вторичный гиперпаратиреоз, гемодиализ, цинакалцет, севеламер, тиосульфат натрия, calcific uremic arteriolopathy, calciphylaxis, secondary hyperparathyroidism, haemodialysis, cinacalcet, sevelamer, sodium thiosulfate

1. Amuluru L, High W, Hiatt K, et al. Metal deposition in calcific uremic arteriolopathy. J Am Acad Dermatol. 2009: 61:73.

2. Arch-Ferrer JE, Beenken SW, Rue LW, et al. Therapy for calciphylaxis: an outcome analysis. Surgeryю 2003: 134:941.

3. Asirvatham S, Sebastian C, Sivaram C, et al. Aortic valve involvement in calciphylaxis: uremic small artery disease with medial calcification and intimal hyperplasia. Am. J. Kidney Dis. 1998. 32: 499-502.

4. Baldwin C, Farah M, Leung M, et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis. 2011: 58:988.

5. Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998. 32: 376.

6. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol. 2000. 54: 318.

7. Brandenburg VM, Kramann R, Specht P, et al. Calciphylaxis in CKD and beyond. Nephrol Dial Transplant. 2012. 27: 1314-1318.

8. Brucculeri M, Cheigh J, Bauer G, et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial. 2005. 18(5): 431-4.

9. Chan YL, Mahony JF, Turner JJ, et al. The vascular lesions associated with skin necrosis in renal disease. Br. J. Dermatol. 1983. 109: 85-95.

10. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kid Int. 2002. 62: 245.

11. Cicone JS, Petronis JB, Embert CD, et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004. 43(6): 1104-8.

12. Coates T, Kirkland G, Dymock R, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am. J. Kidney Dis. 1998. 32: 384-391.

13. Edelstein CL, Wickham MK, Kirby PA. Systemic calciphylaxis presenting as a painful, proximal myopathy. Postgrad Med J. 1992. 68: 209.

14. El-Abbadi M, Giachelli C.М. Mechanisms of vascular calcification. Adv Chronic Kidney Dis. 2007. 14: 54-66.

15. Farah M, Crawford RI, Levin A, et al. Calciphylaxis in the current era: emerging ‘ironic’ features? Nephrol Dial Transplant. 2011. 26: 191.

16. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002. 61: 2210.

17. Fischer AH, Morris DJ. Pathogenesis of calciphylaxis: study of three cases with literature review. Hum Pathol. 1995. 26: 1055.

18. Giachelli CM, Speer MY, Li X, et al. Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res. 2005. 96: 717-722.

19. Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001. 130: 645.

20. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012. 27: 1580.

21. Ibels LS, Alfrey AC, Huffer WE, et al. 3rd: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med. 1979. 66: 790-796.

22. Janigan DT, Hirsch DJ, Klassen GA, et al. Calcified subcutaneous arterioles with infarcts of the subcutis and skin («calciphylaxis») in chronic renal failure. Am J Kidney Dis. 2000. 35: 588.

23. Kang AS, McCarthy JT, Rowland C, et al. Is calciphylaxis best treated surgically or medically? Surgery. 2000. 128: 967.

24. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A con-centrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003. 361(9360): 827-33.

25. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am. J. Kidney Dis. 1998. 32: 384-391.

26. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997. 386: 78.

27. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001. 60: 324.

28. Mehta RL, Scott G, Sloand JA, et al. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med. 1990. 88: 252.

29. Monney P, Nguyen Q, Perroud H, et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant. 2004. 19(8): 2130-2.

30. Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013. 8: 1162.

31. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008. 3: 1139.

32. Peter W, Edward J et al. Calciphylaxis (calcific uremic arteriolopathy) Literature review current through. 2013. 7(2): 2-6.

33. Raggi P, Chertow G, Torres U, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Neph Dial Transpl. 2011. 26(4): 1327-39.

34. Robinson MR, Augustine JJ, Korman NJ. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol. 2007. 143:152.

35. Rostaing L, el Feki S, Delisle MB, et al. Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol. 1995. 15: 524.

36. Selye H. Calciphylaxis. University of Chicago Press, 1962: 1-16.

37. Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol. 2006. 155: 1295.

38. Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kid Dis. 2006. 48(1): 151-4.

39. Torregrosa J, Duran C, Barros X, et al. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia. 2012. 32: 329-334.

40. Velasco N, MacGregor MS, Innes A, et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant. 2006. 21: 1999.

41. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells-a cell system which resembles the system in bone cells. Thromb Haemost. 1999. 82: 1764.

42. Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007. 56: 569.

43. Wong J, Laumann A, Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. J Am Acad Dermatol. 2000. 42: 849.